ProKidney Discloses $141.9M Cash, Runway Into Mid-2027, and Lifted PROACT 1 Enrollment Target
PROK sits 31% above its 52-week low of $0.87.
Summary
ProKidney reported $141.9 million in cash as of September 30, 2026 and said it funds operations into mid-2027, past the Q2 2027 PROACT 1 topline readout. The updated presentation also lifts the Phase 3 enrollment target to over 500 patients and sets a Q1 2028 BLA submission.
Key Events · Earnings and Guidance · PROK
-
Q3 Cash of $141.9M Disclosed
Cash, cash equivalents and marketable securities totaled $141.9 million as of September 30, 2026, with 302,381,712 Class A and Class B shares outstanding as of November 6, 2026.
-
Runway Extended Into Mid-2027
Management expects current cash to fund operations into mid-2027, carrying the company past the Q2 2027 PROACT 1 topline readout — the first time this runway has been stated publicly after the prior 10-Q's going-concern warning.
-
PROACT 1 Enrollment Target Raised
Full enrollment is now expected to exceed 500 patients, up from 470, driven by faster recruitment in mid-2026, with completion targeted for Q1 2027.
-
Milestone Path to BLA
Q2 2027 topline on the eGFR slope surrogate endpoint (efficacy analysis set ~320 patients), Q1 2028 BLA submission, 1H 2029 accelerated approval and launch, and 2H 2029 confirmatory composite endpoint readout.
Analysis · PROK · Life Sciences
The whole investment case hinges on the Q2 2027 PROACT 1 topline readout, and management now says the $141.9 million cash balance as of September 30, 2026 funds operations into mid-2027 — past that binary event. That matters because the last 10-Q carried a going-concern warning about surviving the next 12 months without new funding; this disclosure pushes the funding gap beyond the data readout, reducing the odds of a heavily dilutive raise before it. The presentation also raises the enrollment target to over 500 patients from 470 and lays out a Q1 2028 BLA submission and 1H 2029 launch. Against that, the $200 million Jefferies ATM and $650 million shelf filed October 29 remain an overhang: the runway claim assumes no major new spending, and any capital raised through the ATM would dilute holders at $1.14.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PROK was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $344.7M. The 52-week trading range was $0.87 to $2.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.